{
    "nct_id": "NCT03764293",
    "official_title": "A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy",
    "inclusion_criteria": "* Histopathologically or cytologically confirmed advanced HCC\n* No previous systematic treatment for HCC\n* Have at least one measurable lesion (in accordance with RECIST v1.1)\n* BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy\n* ECOG-PS score 0 or 1\n* Child-Pugh Class: Grade A\n* Life Expectancy of at least 12 weeks\n* Subjects with HBV infection: HBV DNA<500 IU/ml or < 2500 copy/mL, and have received anti-HBV therapy for at least 14 days prior to enrollment in the study\n* Subjects with HCV-RNA(+) must receive antiviral therapy\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously\n* Moderate-to-severe ascites with clinical symptoms\n* History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage\n* Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment\n* Known genetic or acquired hemorrhage or thrombotic tendency\n* Thrombosis or thromboembolic event within 6 months prior to the start of study treatment\n* Cardiac clinical symptom or disease that is not well controlled\n* Hypertension that can not be well controlled through antihypertensive drugs\n* Factors to affect oral administration\n* History of hepatic encephalopathy\n* Previous or current presence of metastasis to central nervous system\n* HIV infection\n* Combined hepatitis B and hepatitis C co-infection\n* Be ready for or previously received organ or allogenic bone marrow transplantation\n* Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity\n* Active known, or suspected autoimmune disease\n* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of first administration of study treatment\n* Use of potent CYP3A4 inducers or inhibitors within 2 weeks prior to the signature of ICF\n* Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug\n* Severe infection within 4 weeks prior to the start of study treatment\n* Palliative radiotherapy for non-target lesions to control symptoms is allowed, but it must be completed at least 2 weeks prior to the start of study treatment\n* Treatment of other investigational product(s) within 28 days prior to the start of study treatment",
    "miscellaneous_criteria": ""
}